Biointerface engineering nanoplatforms for cancer-targeted drug delivery

Zhang, Huaiyu; Dong, Shujun; Li, Zhongmin; Feng, Xiangru; Xu, Weiguo; Tulinao, Catrina Mae S; Jiang, Yang; Ding, Jianxun

doi:10.1016/j.ajps.2019.11.004

Cited by 58 publications

(47 citation statements)

References 129 publications

(187 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conventional dose-delivery of therapeutic agents require frequent administration to provide the proper therapeutic dosage, above the minimum therapeutic level and below the minimum toxic level [30]. However, bioavailability of the drugs and dose-dependent side effects are some of many limitations of the traditional drug delivery methods, like oral or intravenous injections [30][31][32][33][34][35]. To overcome these limitations, controlled drug delivery systems are being explored in different applications, specially cancer treatment.…”

Section: Discussionmentioning

confidence: 99%

Novel Honokiol-eluting PLGA-based scaffold effectively restricts the growth of renal cancer cells

et al. 2020

View full text Add to dashboard Cite

Renal Cell Carcinoma (RCC) often becomes resistant to targeted therapies, and in addition, dose-dependent toxicities limit the effectiveness of therapeutic agents. Therefore, identifying novel drug delivery approaches to achieve optimal dosing of therapeutic agents can be beneficial in managing toxicities and to attain optimal therapeutic effects. Previously, we have demonstrated that Honokiol, a natural compound with potent anti-tumorigenic and anti-inflammatory effects, can induce cancer cell apoptosis and inhibit the growth of renal tumors in vivo. In cancer treatment, implant-based drug delivery systems can be used for gradual and sustained delivery of therapeutic agents like Honokiol to minimize systemic toxicity. Electrospun polymeric fibrous scaffolds are ideal candidates to be used as drug implants due to their favorable morphological properties such as high surface to volume ratio, flexibility and ease of fabrication. In this study, we fabricated Honokiol-loaded Poly(lactide-co-glycolide) (PLGA) electrospun scaffolds; and evaluated their structural characterization and biological activity. Proton nuclear magnetic resonance data proved the existence of Honokiol in the drug loaded polymeric scaffolds. The release kinetics showed that only 24% of the loaded Honokiol were released in 24hr, suggesting that sustained delivery of Honokiol is feasible. We calculated the cumulative concentration of the Honokiol released from the scaffold in 24hr; and the extent of renal cancer cell apoptosis induced with the released Honokiol is similar to an equivalent concentration of direct application of Honokiol. Also, Honokiol-loaded scaffolds placed directly in renal cell culture inhibited renal cancer cell proliferation and migration. Together, we demonstrate that Honokiol delivered through electrospun PLGA-based scaffolds is effective in inhibiting the growth of renal cancer cells; and our data necessitates further in vivo studies to explore the potential of sustained release of therapeutic agents-loaded electrospun scaffolds in the treatment of RCC and other cancer types.

show abstract

Section: Discussionmentioning

confidence: 99%

Novel Honokiol-eluting PLGA-based scaffold effectively restricts the growth of renal cancer cells

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Thiolated heparin-pheophorbide A (PhA) conjugated magnetic iron oxide/gold hybrid nanoparticle Therapeutics Phototoxicity and strong fluorescence signals from the NPs result in A549 cells deaths under light irradiation. [23] 3.…”

Section: Hypericin-bearing Magnetic Iron Oxide Nanoparticles Therapeumentioning

confidence: 99%

“…Active Targeting: The basis of active targeting strategy includes the interaction of ligand-stocked drug carrier with surface-exposed receptors on the target cells, which helps in their assemblage in a tumor, and also assists their intracellular accretion through receptor-mediated endocytosis [ 21 ]. Tumor cells are usually overexpressed with one or more types of specific receptors which may act as a target site for the active targeting through ligand-functionalized nanoparticles [ 22 , 23 ]. Thus, the tumor and endothelial cells are recognized as cellular targets for active targeting approach.…”

Section: Cancer Nanotechnology: Contemporary Research In Diagnosismentioning

confidence: 99%

Progress of Cancer Nanotechnology as Diagnostics, Therapeutics, and Theranostics Nanomedicine: Preclinical Promise and Translational Challenges

et al. 2020

View full text Add to dashboard Cite

Early detection, right therapeutic intervention, and simultaneous effectiveness mapping are considered the critical factors in successful cancer therapy. Nevertheless, these factors experience the limitations of conventional cancer diagnostics and therapeutics delivery approaches. Along with providing the targeted therapeutics delivery, advances in nanomedicines have allowed the combination of therapy and diagnostics in a single system (called cancer theranostics). This paper discusses the progress in the pre-clinical and clinical development of therapeutics, diagnostics, and theranostics cancer nanomedicines. It has been well evident that compared to the overabundance of works that claimed success in pre-clinical studies, merely 15 and around 75 cancer nanomedicines are approved, and currently under clinical trials, respectively. Thus, we also brief the critical bottlenecks in the successful clinical translation of cancer nanomedicines.

show abstract

“…New approaches for cancer immunotherapy are needed to promote the therapeutic potential of therapeutic payloads through a safer and more controlled manner. A large and growing body of studies have demonstrated the synergistic effects of biomaterials combined with cancer immunotherapy direct the path to address these limitations (Guo et al, 2020;Sang et al, 2019;Zhang et al, 2020). Lately, a variety of biomaterials, such as nanoparticles, implantable biomaterial scaffolds and injectable biomaterial scaffolds, have been introduced to promote immune response and improve the anti-tumor effect (Feng et al, 2020;Li et al, 2019;Wang et al, 2020;Xie et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

Implantable and Injectable Biomaterial Scaffolds for Cancer Immunotherapy

Luo

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Cancer immunotherapy has become an emerging strategy recently producing durable immune responses in patients with varieties of malignant tumors. However, the main limitation for the broad application of immunotherapies still to reduce side effects by controlling and regulating the immune system. In order to improve both efficacy and safety, biomaterials have been applied to immunotherapies for the specific modulation of immune cells and the immunosuppressive tumor microenvironment. Recently, researchers have constantly developed biomaterials with new structures, properties and functions. This review provides the most recent advances in the delivery strategies of immunotherapies based on localized biomaterials, focusing on the implantable and injectable biomaterial scaffolds. Finally, the challenges and prospects of applying implantable and injectable biomaterial scaffolds in the development of future cancer immunotherapies are discussed.

show abstract

Biointerface engineering nanoplatforms for cancer-targeted drug delivery

Cited by 58 publications

References 129 publications

Novel Honokiol-eluting PLGA-based scaffold effectively restricts the growth of renal cancer cells

Novel Honokiol-eluting PLGA-based scaffold effectively restricts the growth of renal cancer cells

Progress of Cancer Nanotechnology as Diagnostics, Therapeutics, and Theranostics Nanomedicine: Preclinical Promise and Translational Challenges

Implantable and Injectable Biomaterial Scaffolds for Cancer Immunotherapy

Contact Info

Product

Resources

About